File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical and pathological significance of the integrin α5β1 expression in endometrial adenocarcinoma

TitleClinical and pathological significance of the integrin α5β1 expression in endometrial adenocarcinoma
Authors
KeywordsEndometrial Adenocarcinoma
Immunohistochemistry
Integrin Α5β1
Issue Date2001
Citation
Fudan University Journal of Medical Sciences, 2001, v. 28 n. 3, p. 251-253 How to Cite?
AbstractPurpose: To investigate the integrin α5β1 expression in endometrial adenocarcinoma and its relation with tumor differentiation, invasion, metastasis and prognosis. Methods: The integrin α5β1 expression was detected in 92 cases of endometrial adenocarcinoma by immunohistochemistry technique (PAP method). Results: The expression of integrin α5β1 in 77.1% cases with endometrial adenocarcinoma were weaker or loss. The positive rate of integrin α5β1 was lower in poorly differentiated carcinoma group than in well differentiated group (P < 0.05). The positive rate of integrin α5β1 was lower in lymph-node metastatic group than in nonmetastatic group (P < 0.05). The five-year survival rate of integrin α5β1 positive group was higher in integrin α5β1 positive group (78.4%) than that in negative group (19.2%, P< 0.05). Conclusions: The weak or loss expression of integrin α5β1 was correlated with differentiation and metastasis of endometrial adenocarcinoma. The expression of integrin α5β1 may have prognostic value.
Persistent Identifierhttp://hdl.handle.net/10722/90894
ISSN
2015 SCImago Journal Rankings: 0.105
References

 

DC FieldValueLanguage
dc.contributor.authorLi, Jen_HK
dc.contributor.authorLin, Ben_HK
dc.contributor.authorZhang, X-Ren_HK
dc.contributor.authorGao, Ten_HK
dc.contributor.authorZhao, Z-Hen_HK
dc.date.accessioned2010-09-17T10:09:58Z-
dc.date.available2010-09-17T10:09:58Z-
dc.date.issued2001en_HK
dc.identifier.citationFudan University Journal of Medical Sciences, 2001, v. 28 n. 3, p. 251-253en_HK
dc.identifier.issn1672-8467en_HK
dc.identifier.urihttp://hdl.handle.net/10722/90894-
dc.description.abstractPurpose: To investigate the integrin α5β1 expression in endometrial adenocarcinoma and its relation with tumor differentiation, invasion, metastasis and prognosis. Methods: The integrin α5β1 expression was detected in 92 cases of endometrial adenocarcinoma by immunohistochemistry technique (PAP method). Results: The expression of integrin α5β1 in 77.1% cases with endometrial adenocarcinoma were weaker or loss. The positive rate of integrin α5β1 was lower in poorly differentiated carcinoma group than in well differentiated group (P < 0.05). The positive rate of integrin α5β1 was lower in lymph-node metastatic group than in nonmetastatic group (P < 0.05). The five-year survival rate of integrin α5β1 positive group was higher in integrin α5β1 positive group (78.4%) than that in negative group (19.2%, P< 0.05). Conclusions: The weak or loss expression of integrin α5β1 was correlated with differentiation and metastasis of endometrial adenocarcinoma. The expression of integrin α5β1 may have prognostic value.en_HK
dc.languageengen_HK
dc.relation.ispartofFudan University Journal of Medical Sciencesen_HK
dc.subjectEndometrial Adenocarcinomaen_HK
dc.subjectImmunohistochemistryen_HK
dc.subjectIntegrin Α5β1en_HK
dc.titleClinical and pathological significance of the integrin α5β1 expression in endometrial adenocarcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailLin, B:blin@hku.hken_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.scopuseid_2-s2.0-0042823480en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0042823480&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume28en_HK
dc.identifier.issue3en_HK
dc.identifier.spage251en_HK
dc.identifier.epage253en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats